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Alpha1-Pi deficiency is a widely under-recognized disease.
In most European countries and in the U.S.A. it is
estimated that only 5–10% of individuals with severe
deficiency are identified. This, however, hampers necessary
lifestyle changes to be made, such as smoking cessation,
occupational changes and genetic counselling for couples at
risk. The WHO recommended intensified testing and
suggested that patients with COPD and asthma should be
screened for a1-Pi deficiency (1). This is based on data in
which 2–3% of patients with COPD were found to be
homozygous for the most common a1-Pi deficiency allele
PiZ (2). The WHO recommended that ‘. . . all patients with
COPD and adults as well as adolescents with asthma
should be screened once in their life for a1-antitrypsin
deficiency, using a quantitative test’ (i.e. an immunoassay).
Patients with abnormal results on the quantitative test
should then undergo Pi typing to identify the phenotype.
On the basis of this recommendation we planned a study
in which a large outpatient population of COPD and
asthma patients were screened for a1-Pi deficiency in seven
private practices. The aim of this study was to identify the
frequency of a1-Pi deficiency in a target population in
Germany using a dried blood spot test for a1-Pi levels and
isoelectric focusing (IEF). This allowed us to evaluate the
feasibility of collecting large numbers of samples with this
method and the shipment abroad.
The advantage of using the dried blood spot method with
small amounts of blood was the lack of need for a skilled
phlebotomist. Sampling and handling is also greatly
improved and transportation of these samples can be easily
done by regular mail with no refrigeration required.
Methods
We recruited patients from three pneumologists and four
general practitioners in, or close to, Essen, Germany, and
looked at their a1-Pi levels and phenotypes. Patients with
COPD, pulmonary emphysema, asthma or bronchiectasis
were recruited and demographic data was collected.
Patients gave informed consent and samples were either
taken from the hyperemic earlobe or from a finger and
placed on the filter paper. Included was a questionnaireCorrespondence should be addressed to: M. Wencker, Department
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nosis. Dried blood spots were then transported to and
analysed at the AAT Deficiency Detection Center in Salt
Lake City, UT, U.S.A.
A defined volume of filter paper was used to elute serum
for the quantitative a1-Pi levels. Similarly, dried blood spots
were used to elute either a1-Pi protein for IEF or DNA for
genotyping. In this study, IEF was carried out on all
samples regardless of serum a1-Pi levels to determine the
frequency of heterozygotes. In the case of equivocal results
some samples required additional genotyping.
Results
More than 1000 samples were collected in a short period of
time. The quality of the blood spots was excellent in most
cases. Any problems with the samples was usually caused
by not spotting carefully. In these cases the amount of
blood on the filter paper was too small to do a quantitative
analysis. In a vast majority of the cases there was enough
dried blood to do a1-Pi levels and phenotypes. No problems
were encountered with the shipment of samples.
The mean patient age was 52 years, with a wide
scattering, and about half of the patients were male. A
proportion were ex-smokers but, surprisingly, more than
40% were non-smokers. The ratio of relatives with known
a1-antitrypsin deficiency was very low. The patient usually
reported to their doctor’s oce because of dyspnoea on
exertion. A large proportion had chronic cough and
phlegm, asthmatic attacks and wheezing. The physicians’
diagnosis given for these patients was more than 40%
asthma, 35% chronic obstructive bronchitis, 27% emphy-
sema and more rarely, chronic bronchitis, acute bronchitis
and a few patients with bronchiectasis. Even though the
analysis of the samples is not complete, the preliminary
results show a percentage of homozygous PiZ of signifi-
cantly less than 1% which are lower than the expected
2–3%, according to previous results (2). A few samples are
being genotyped because of equivocal findings, with results
still pending.
In conclusion, the participating physicians did a very
good job recruiting patients with COPD and asthma as
recommended by the WHO. In general, few problems were
encountered sampling the blood spots and transatlantic
shipping did not compromise the quality of the samples.
The dried blood spot test was very well-suited to do large
scale screening; however, the identification rate in this
patient sample seems to be lower than previously reported.# 2000 HARCOURT PUBLISHERS LTD
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